Engineering of microcomplex of artemether and lumefantrine for effective drug treatment in malaria

Figures & data

Table 1. Particle size and zeta potential.

Sample	Particle size (nm ± SD)	Zeta potential (mV ± SD)
Artemether	1143 ± 22.67	–21 ± 1.74
Lumefantrine	2551 ± 27.3	–12.7 ± 3.74
F1	694.4 ± 17.82	–10.4 ± 2.76
F2	1894 ± 6.4	–10.4 ± 1.22
F3	1047 ± 11.50	–19.7 ± 2.49

Figure 1. SEM photographs of formulations (A) F1, (B) F2 and (C) F3.

Figure 2. Solubility studies of drugs and formulations.

Figure 3. In-vitro drug release profile of artemether and lumefantrine from formulations F1, F2 and F3.

Figure 4. FTIR Spectra of formulations (A) F1, (B) F2 and (C) F3.

Figure 5. DSC thermographs of formulations (A) F1, (B) F2 and (C) F3.

Table 2. Stability study of formulations F1, F2 and F3.

Time point	Formulation	Particle size (μm ± S.D.)	% Entrapment Efficiency	% In-vitro drug release
1 month	F1	692.4 ± 13.56	61.5 ± 1.68%	83.45 ± 1.32%
	F2	1888.1 ± 5.7	57.65 ± 2.17%	92.44 ± 1.75%
	F3	1039.2 ± 10.70	85.3 ± 1.88% for artemether and 90.87 ± 2.17% for lumefantrine	85.55 ± 1.32% for artemether and 90.26 ± 1.75% for lumefantrine

Figure 6. In-vitro drug release profile of artemether and lumefantrine from formulation F4.

Figure 7. In-vivo drug release profile of formulations.